Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice
- PMID: 18034421
- DOI: 10.1002/eji.200737143
Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice
Abstract
The pathological DNA-specific B lymphocytes in lupus are logical targets for a selected therapeutic intervention. We have hypothesized that it should be possible to suppress selectively the activity of these B cells in lupus mice by administering to them an artificial molecule that cross-links their surface immunoglobulins with the inhibitory FcgammaIIb surface receptors. A hybrid molecule was constructed by coupling the DNA-mimicking DWEYSVWLSN peptide to a monoclonal anti-mouse FcgammaRIIb antibody. This chimeric antibody was added to cultured spleen cells from sick MRL/lpr mice, immunized with diphtheria toxoid, resulting in reduction of the numbers of anti-DNA but not of anti-diphtheria IgG antibody-producing cells. Intravenous infusions with the DNA-peptide antibody chimera to 7-wk-old animals prevented the appearance of IgG anti-DNA antibodies and of albuminuria in the next 2 months. The administration of the DNA-peptide chimeric antibody to 18 wk-old mice with full-blown disease resulted in the maintenance of a flat level of IgG anti-DNA antibodies and in delay of the aggravation of the lupus glomerulonephritis. The use of chimeric antibodies targeting inhibitory B lymphocyte receptors represents a novel approach for the selective suppression of autoreactive disease-associated B cells in autoimmune diseases.
Similar articles
-
Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity.Mol Immunol. 2009 Nov;47(1):123-30. doi: 10.1016/j.molimm.2009.01.013. Epub 2009 Feb 24. Mol Immunol. 2009. PMID: 19243823
-
Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor.Int Immunol. 2008 Feb;20(2):165-75. doi: 10.1093/intimm/dxm133. Epub 2007 Dec 21. Int Immunol. 2008. PMID: 18156625
-
Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity.Lupus. 2010 Oct;19(11):1261-71. doi: 10.1177/0961203310371153. Epub 2010 Jun 8. Lupus. 2010. PMID: 20530521
-
Selective silencing of autoreactive B lymphocytes-Following the Nature's way.Autoimmun Rev. 2010 Sep;9(11):775-9. doi: 10.1016/j.autrev.2010.06.010. Epub 2010 Jul 1. Autoimmun Rev. 2010. PMID: 20601201 Review.
-
Anti-nucleosome antibodies and T-cell response in systemic lupus erythematosus.Ann Med Interne (Paris). 2002 Dec;153(8):513-9. Ann Med Interne (Paris). 2002. PMID: 12610425 Review.
Cited by
-
Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity.Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10255-9. doi: 10.1073/pnas.1103555108. Epub 2011 Jun 6. Proc Natl Acad Sci U S A. 2011. PMID: 21646518 Free PMC article.
-
Lupus progression deteriorates oogenesis quality in MRL/lpr mice.Immunol Res. 2024 Aug;72(4):811-827. doi: 10.1007/s12026-024-09489-2. Epub 2024 May 21. Immunol Res. 2024. PMID: 38771487
-
Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus.Exp Mol Med. 2017 Sep 29;49(9):e381. doi: 10.1038/emm.2017.144. Exp Mol Med. 2017. PMID: 28960214 Free PMC article.
-
Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes.Immunol Res. 2014 Oct;60(1):23-34. doi: 10.1007/s12026-014-8489-0. Immunol Res. 2014. PMID: 24515613
-
Modulation of autoimmunity with artificial peptides.Autoimmun Rev. 2010 Nov;10(1):18-21. doi: 10.1016/j.autrev.2010.08.017. Epub 2010 Aug 31. Autoimmun Rev. 2010. PMID: 20807590 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
